Bayer (BAYRY) announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK inhibitor.The drug is now fully approved in the United States for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that has spread or for those who are not eligible for surgery. The drug was approved for patients who did not have any satisfactory alternative treatment or ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Se ...

Bayer’s (BAYRY) wholly owned and independently operated subsidiary, Vividion Therapeutics, Inc, announced that the first patient has been dosed in a phase I study evaluating VVD-159642.VVD-159642 is an investigational oral inhibitor designed to target RAS-driven cancers.The phase I study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either Lumakras (sotorasib) or trametinib in patients wi ...

智通财经记者 | 黄华 在2022年-2024年期间，华领医药的营收年年大幅增长，但其亏损额始终保持在一年2亿元的水平。期间，公司的销售费 用和研发费用均在持续增长。此前，华领医药在2024年中报中称，企业目标是在2025年实现盈利。 对于前述事项，在2024年业绩公告中，华领医药表示，在与拜耳终止独家推广服务协议后，未摊销合约负债人民币 12.43亿元将确认为公司于2025年的收益。 截至3月28日午市收盘，华领医药报2.54港元/股，跌1.55%，市值约26亿港元。 智通财经编辑 | 谢欣 3月27日，华领医药发布2024年度业绩数据称，公司于期内实现销售收入2.56亿元，同比增加234%。该公司的降糖药多 格列艾汀片（商品名：华堂宁）销售表现良好，帮助企业的年收入首度破亿。这也是华堂宁被纳入国家医保药品目录后 的首个完整年。 自今年1月起，华领医药已从合作伙伴拜耳手中在国内的商业化工作。在截至2月末的两个月内，华堂宁的销售数量达到 59.2万盒，实现销售净额约7320万元。 相比之下，在2024年的前两个月内，华堂宁的销售数量和销售净额分别为20.2万盒、2450万元。这意味着，在产品单价 维持不变的状 ...

Bayer (BAYRY) announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou Puhe BioPharma is focused on the research and development of innovative small-molecule precision therapeutics.The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine phosphorylase (MTAP)-deleted tumors.Under the agreement, Bayer obtained an exclusive worldwide ...

A downtrend has been apparent in Bayer Aktiengesellschaft (BAYRY) lately. While the stock has lost 6.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish ...

Shares of pharma conglomerate Bayer (BAYRY) were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff.Bayer has been ordered by the jury to pay $2.1 billion to the plaintiff ($2 billion in punitive damages and $65 million in compensatory damages).However, the company disagreed with the jury’s verdict.In the past year, shares of ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is one of 1011 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on ...

Core Insights - Bayer Aktiengesellschaft has not been a strong investment over the past few years, indicating potential challenges in its market performance [1] Group 1: Company Overview - Bayer is a German pharmaceutical and life science company, focusing on high-quality companies that can outperform the market due to competitive advantages and defensibility [1] Group 2: Analyst Background - The analysis is conducted by an individual with a Master's Degree in Sociology, emphasizing organizational and economic sociology, and a Bachelor's Degree in Sociology and History [1]